Cargando…
Case study of a critically ill person with COVID-19 on ECMO successfully treated with leronlimab
The number of confirmed cases of infection with SARS-CoV-2, the virus causing Coronavirus disease 2019 (COVID-19), continues to increase and is associated with substantial morbidity and mortality in virtually every country in the world. Although in the long-term mass vaccinations remains the most pr...
Autores principales: | Elneil, Sohier, Lalezari, Jacob P., Pourhassan, Nader Z. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7985604/ https://www.ncbi.nlm.nih.gov/pubmed/33778462 http://dx.doi.org/10.1016/j.jtauto.2021.100097 |
Ejemplares similares
-
Disruption of CCR5 signaling to treat COVID-19-associated cytokine storm: Case series of four critically ill patients treated with leronlimab
por: Agresti, Nicholas, et al.
Publicado: (2021) -
LERONLIMAB AND THE ROLE OF CCR5 SUPRESSION IN COVID-19 TREATMENT
por: BJORK, SARAH, et al.
Publicado: (2021) -
Suppression of human and simian immunodeficiency virus replication with the CCR5-specific antibody Leronlimab in two species
por: Chang, Xiao L., et al.
Publicado: (2022) -
ECMO for Critically Ill COVID-19 with ARDS: A Case Series
por: Rai, D., et al.
Publicado: (2021) -
Extracorporeal hemoadsorption in critically ill COVID-19 patients on VV ECMO: the CytoSorb therapy in COVID-19 (CTC) registry
por: Hayanga, J. W. Awori, et al.
Publicado: (2023)